Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay.
Antibodies to neuraminidase (NA), the second most abundant surface protein on influenza virus, contribute toward protection against influenza. Traditional methods to measure NA inhibiting (NI) antibody titers are not practical for routine serology. This protocol describes the enzyme-linked lectin assay (ELLA), a practical alternative method to measure NI titers that is performed in 96 well plates coated with a large glycoprotein substrate, fetuin. NA cleaves terminal sialic acids from fetuin, exposing the penultimate sugar, galactose. Peanut agglutinin (PNA) is a lectin with specificity for galactose and therefore the extent of desialylation can be quantified using a PNA-horseradish peroxidase conjugate, followed by addition of a chromogenic peroxidase substrate. The optical density that is measured is proportional to NA activity. To measure NI antibody titers, serial dilutions of sera are incubated at 37 °C O/N on fetuin-coated plates with a fixed amount of NA. The reciprocal of the highest serum dilution that results in ≥50% inhibition of NA activity is designated as the NI antibody titer. The ELLA provides a practical format for routine evaluation of human antibody responses following influenza infection or vaccination.
Division of Viral Products, CBER, Food and Drug Administration.
Jin
J
Gao
Division of Viral Products, CBER, Food and Drug Administration.
Laura
L
Couzens
Division of Viral Products, CBER, Food and Drug Administration; Maryna.Eichelberger@fda.hhs.gov.
Maryna C
MC
Eichelberger
D000914:Antibodies, Viral; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D007252:Influenza Vaccines; D007251:Influenza, Human; D037102:Lectins; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D009975:Orthomyxoviridae
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D037102:Lectins; D009439:Neuraminidase
J Virol. 1968 Apr;2(4):281-8
4911843
N Engl J Med. 1972 Jun 22;286(25):1329-32
5027388
J Infect Dis. 2015 Oct 15;212(8):1191-9
25858957
Vaccine. 2010 Feb 25;28(9):2076-9
20044052
J Virol. 1968 Aug;2(8):778-86
5701819
N Engl J Med. 2013 Dec 26;369(26):2564-6
24224560
J Virol Methods. 2014 Dec 15;210:7-14
25233882
J Virol Methods. 2015 Jun 1;217:55-63
25712563
Influenza Other Respir Viruses. 2009 Sep;3(5):233-40
21462400
Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072
25734142
J Infect Dis. 2013 Mar 15;207(6):974-81
23307936
J Immunol Methods. 1990 Dec 31;135(1-2):49-57
1703190
J Virol. 1969 Oct;4(4):528-34
5823234
Vaccine. 2016 Jan 20;34(4):458-65
26707221
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
10801978
J Infect Dis. 2012 Jan 1;205(1):28-34
22090447